Month: September 2026

• HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical’s newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical’s headquarters in Boston ahead of deployment in HOPE’s Florida clinics
• The Zeta TMS Robotic System’s AI-driven software adjusts the TMS coil in real time with submillimeter precision, building on the Zeta TMS Navigation System HOPE implemented earlier this summer
• Deployment supports SPARC-TMS, NRx’s trial of NRX-101 with robotic TMS, for which NRx is initiating a project for the military, in partnership with Harvard McClean Hospital.
• NRx Pharmaceuticals is participating in a fireside chat at the 2026 Cantor Global Healthcare Conference today at 8:35 a.m. ET; a live webcast is available on the Events page of the Company’s website at ir.nrxpharma.com/events

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, “NRx” or the “Company”), a clinical-stage biopharmaceutical company, today announced that its subsidiary, HOPE Therapeutics, Inc. (“HOPE”), will be the first Interventional Psychiatry to deploy Zeta Surgical’s newly FDA-cleared Zeta TMS Robotic System, with clinical staff now in training ahead of deployment in Florida.

“Deploying the first FDA-cleared robotic TMS system moves the HOPE model another step from concept to clinical reality,” said Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and HOPE Therapeutics. “Not all TMS is delivered the same way, and the difference between precise, repeatable targeting and approximation is exactly what patients and clinicians should be asking about. With this advance, our clinicians will be able to deliver neurosurgical-grade precision to every patient, in every session, without depending on the patient staying perfectly still or on a technician precisely holding the coil. That same capability is the foundation of our now-FDA cleared SPARC-TMS trial to be conducted in military and civilian settings. Our goal is to achieve measurable, rapid, and durable remission from depression.”

In June 2026, HOPE became the first commercial site in the United States to treat patients with the Zeta TMS Navigation System, which uses AI-driven image guidance to track the patient’s head in real time and show the clinician exactly where the coil sits relative to the MRI-guided brain target. The Zeta TMS Robotic System, which received FDA 510(k) clearance in July 2026, builds on that foundation. It places the coil in a robotic arm, originally approved for neurosurgery, tracks the patient’s movement, and constantly refocuses the TMS energy with submillimeter precision.

The deployment supports SPARC-TMS, NRx’s FDA-approved Phase 2/3 trial of NRX-101 in combination with robotic TMS (NCT07227103). NRx was selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for SPARC-TMS, subject to completion of contracting. The trial is planned across a leading US academic teaching hospital, multiple HOPE Therapeutics clinics, and two military treatment facilities.

TMS is a non-invasive therapy used primarily for treatment-resistant depression, which affects approximately one-third of patients with major depressive disorder. Accurate and repeatable targeting of patient-specific treatment sites is an important component of treatment delivery.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

About HOPE Therapeutics

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), is a provider of advanced psychiatric and neurological care, specializing in evidence-based treatments for major depressive disorder, anxiety, and other complex neurological conditions. Operating out of state-of-the-art clinics, HOPE Therapeutics focuses on improving patient outcomes through the application of modern medical technologies and clinical practices. For more information, please visit www.hopetherapeutics.com.

About ZETA SURGICAL

ZETA SURGICAL is redefining the standard of care for image-guided surgery and targeted neuro-therapeutics. Its navigation and robotics platform applies advanced artificial intelligence and computer vision to enable high-accuracy image guidance across virtually any point of care in minutes, unlocking less invasive and more precise targeted therapies. The Zeta Navigation System, Zeta TMS Navigation System, and Zeta TMS Robotic System are cleared by the FDA and commercially available in the United States. For more information, please visit www.zetasurgical.com.

Media Contact — media@zetasurgical.com

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

Herzliya Israel, Sept. 11, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (Nasdaq: BMR), a leader in video optimization technology and solutions, today announced that it will present virtually at the H.C. Wainwright 28th Annual Global Investment Conference which is being held on September 14-16, 2026 in New York.

Institutional investors and industry professionals can register for the conference, and schedule one-on-one virtual meetings to learn about Beamr’s achievements and activities. The on-demand presentation will be available on the H.C. Wainwright conference website for registered attendees from September 11 at 7:00 A.M. ET.

Beamr is a world leader in content-adaptive video compression trusted by top media companies including Netflix and Paramount. The Company is applying its patented technology, which reduces file sizes by up to 50% while preserving quality for both human viewers and machine vision, across markets where video is essential to business operations and its usage is fast growing, including media and entertainment, machine learning, and autonomous vehicles (AV).

“Earlier this year, we outlined our strategic plan to expand Beamr’s technology into new markets and deepen our presence in the platforms and ecosystems our customers already use. We are now executing on that plan,” said Sharon Carmel, Beamr CEO. “In July, we announced our integration with dSPACE’s RTMaps platform for autonomous vehicle and Physical AI teams, and earlier this week, we announced our partnership with VAST Data to bring AI-enhanced video solutions to media and entertainment workflows. These are important steps in turning our strategy into commercial opportunities across our key markets.”

Review Beamr’s presentation here.

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers.

For more details, please visit www.beamr.com or the investors’ website www.investors.beamr.com and follow us on Linkedin and X.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition, including statements relating to the progress of its strategic plan to expand Beamr’s technology into new markets and deepen its presence in the platforms and ecosystems its customers already use and turning its strategy into commercial opportunities across its key markets. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on February 26, 2026 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
investorrelations@beamr.com

WASHINGTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Public Policy Holding Company, Inc. (“PPHC”, the “Group” or the “Company”) (Nasdaq: PPHC) (AIM: PPHC.L) (ISIN: US7444302084), a leading global strategic communications provider offering a comprehensive range of advisory services in the areas of Government Relations, Public Affairs and Corporate Communications, today announced that its Board of Directors has declared an Interim Dividend for the financial year ending December 31, 2026 of $0.117 per share of Common Stock, an increase of approximately 2% over the 2025 Interim Dividend of $0.115 per share (as adjusted for the Company’s 5-for-1 share consolidation effective October 2, 2025).

The Interim Dividend equates to an aggregate amount, based on the current number of outstanding shares of the Company’s Common Stock, of approximately $3.6 million (2025 Interim Dividend: approximately $2.9 million), payable to the holders of record of all of the issued and outstanding shares of the Company’s Common Stock as of the close of business on the record date, September 25, 2026. The ex-dividend date for shares of the Company’s Common Stock traded on Nasdaq and on AIM is September 25, 2026. The Interim Dividend will be paid no later than October 23, 2026.

The Interim Dividend is consistent with the Company’s dividend policy of paying out up to 30% of Adjusted Net Income, and with the Group’s intention to pay approximately one-third of the expected total dividend for the year as an Interim Dividend. The dividend reflects the Group’s balanced approach to capital allocation, returning cash to stockholders while retaining the flexibility to pursue accretive acquisitions. The Company expects to continue to pay dividends on a semiannual basis; the declaration, timing and amount of any future dividends remain subject to the discretion of the Company’s Board of Directors.

About PPHC

Incorporated in 2014, PPHC is a global strategic communications platform that supports clients in enhancing and defending their reputations, advancing policy objectives, managing regulatory risk, and engaging with federal and state-level policymakers, stakeholders, media, and the public.

Engaged by approximately 1,500 clients, including companies, trade associations and non-governmental organizations, PPHC is active in all major sectors of the economy, including healthcare and pharmaceuticals, financial services, energy, technology, telecommunications and transportation.

With operations across the United States and internationally, PPHC’s services include government relations, public affairs and corporate communications, research and analytics, digital advocacy campaigning, and compliance support. The Company’s shares are admitted to trading on the Nasdaq Global Market and on AIM, a market operated by the London Stock Exchange, under the ticker symbol “PPHC”.

For more information, visit www.pphcompany.com.

Media Contact:

Public Policy Holding Company, Inc.
(202) 688-0020
inquiries@pphcompany.com 

Investor Relations:

Public Policy Holding Company, Inc.
(202) 688-0020
IR@pphcompany.com 

• Company gains further clarity on the additional information required to advance its PMA review

• FDA did not request an additional clinical trial following its 100-day review of the PMA application

• Company does not currently expect a material change to its overall regulatory timeline

TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update following its in-person 100-Day Meeting with the U.S. Food and Drug Administration (“FDA”) regarding the Company’s Premarket Approval (“PMA”) application for Toraymyxin™ (“PMX”).

As part of its substantive review of the PMA, FDA provided Spectral with a deficiency letter several days prior to the Company’s scheduled in-person 100-Day Meeting. Deficiency letters are commonly issued as part of the 100-day PMA review process and are used by FDA to identify additional information necessary to complete its review of an application. The letter identified a number of items requiring additional information, analyses, testing and clarification and provided the Company with the opportunity to focus the 100-Day Meeting discussion on the items identified by FDA.

The Company considered the meeting constructive. Based on the Company’s understanding of the discussion, Spectral has further clarity regarding the additional analyses, testing and information required to address the outstanding items and advance the PMA review. FDA did not request an additional clinical trial as part of the Company’s response to the deficiency letter. FDA’s official minutes of the meeting are the definitive record of the discussion and have not yet been issued.

“We were pleased with the constructive dialogue with FDA during the in-person 100-Day Meeting,” said Chris Seto, Chief Executive Officer of Spectral Medical. “Receiving the deficiency letter in advance of the meeting allowed us to have a focused discussion with FDA regarding the outstanding items. We came away with a clearer understanding of the remaining work required to advance the review of our PMA and are actively progressing the additional analyses, testing and other activities discussed with FDA.”

Spectral is incorporating FDA’s feedback into its ongoing regulatory activities and is finalizing the associated work plan and timing. Based on its current assessment, the Company does not currently expect the additional activities to result in a material change to its overall regulatory timeline. Spectral will provide further updates as appropriate.

About Spectral

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA-cleared Endotoxin Activity Assay (EAA™), the only FDA-cleared test for endotoxin in blood.

PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities, the Company’s ability to satisfactorily address the items identified in FDA’s deficiency letter and the timing thereof, as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information, please contact:

Ali Mahdavi		Chris Seto
Capital Markets & Investor Relations		CEO
Spinnaker Capital Markets Inc.		Spectral Medical Inc.
416-962-3300
am@spinnakercmi.com		cseto@spectraldx.com

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Access the video webcast here

ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. Wainwright 28th Annual Global Investment Conference (the “Conference”) is now available for on-demand viewing here.

The fireside chat features Bob Jahr, Chief Executive Officer of Outlook Therapeutics, and Douglas Tsao, Managing Director and Senior Biotechnology Equity Research Analyst at H.C. Wainwright, discussing the Company’s recent developments.

The on-demand presentation is available for viewing beginning today, September 11, 2026, at 7:00 a.m. ET, and can be accessed through the News & Events page on the Investors section of the Company’s website (outlooktherapeutics.com).

Management will be available on-site at the Conference being held September 14-16, 2026, in New York, NY, to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the Conference. For more information about the Conference, please visit the conference website.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community; Outlook Therapeutics’ development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775

• Sparklight ranks first in 86 internet performance comparisons across 14 states
• Sparklight internet speeds were 50% faster than 5G Home Internet
• Recognitions span speed, responsiveness, network consistency, gaming and video performance
• Findings are based on millions of consumer-initiated tests conducted during the first half of 2026

PHOENIX, Sept. 11, 2026 (GLOBE NEWSWIRE) — Sparklight®, a leading internet and mobile provider, has ranked first in 86 internet performance comparisons across markets in 14 states during the first half of 2026, according to Ookla® Speedtest Intelligence® data.

A custom analysis of Ookla® Speedtest Intelligence® data across Sparklight’s service footprint also found that Sparklight delivered 50% faster download speeds and 73% faster upload speeds than 5G Home Internet.**

The findings are based on millions of consumer-initiated tests conducted from Jan. 1 through June 30, 2026, and reflect real-world network performance across download and upload speeds, responsiveness, network consistency, gaming experience and video experience.

“Our focus is on delivering fast, reliable internet that can keep up with how our customers live, work and connect every day,” said Jim Holanda, Chief Executive Officer of Cable One, Sparklight’s parent company. “These results reinforce the value of the investments we continue to make in our network to expand capacity, broaden Multi-Gig availability and deliver a strong, consistent experience across everything from streaming and gaming to work, entertainment and connected devices.”

KEY FACTS

• Sparklight earned 86 recognitions across Arizona, Idaho, Illinois, Indiana, Kansas, Louisiana, Mississippi, Missouri, New Mexico, North Dakota, Oklahoma, Oregon, South Carolina and Texas for internet performance during the first half of 2026.*
• Sparklight internet download speeds were 50% faster than 5G Home Internet across the company’s service footprint.**
• Sparklight internet upload speeds were 73% faster than 5G Home Internet across the company’s service footprint.**
• The results are from Ookla® Speedtest Intelligence® data from millions of consumer-initiated tests conducted Jan. 1 through June 30, 2026.
• Sparklight received 33 recognitions for Fastest Download Speeds.
• Sparklight received 27 recognitions for Most Responsive Internet Speeds and 16 for Most Reliable Internet Speeds.
• The company also received eight recognitions for Fastest Upload Speeds, one for Best Fixed Gaming Experience and one for Best Fixed Video Experience.
• Sparklight has invested nearly $1 billion over the past three years across its 24-state footprint to increase network capacity, expand Multi-Gig internet availability and enhance reliability.

Speedtest Intelligence data recognizes Sparklight for internet performance

Ookla® is a global leader in connectivity intelligence and the company behind Speedtest®. Speedtest Intelligence® data is derived from consumer-initiated testing and provides information about how internet connections perform in real-world use.

The recognitions evaluate multiple aspects of fixed internet performance rather than speed alone, including responsiveness, reliability, gaming experience and video experience.

In Arizona, Sparklight earned recognition for fastest download and upload speeds, responsiveness and reliability in the Show Low area; fastest upload speeds in Payson; and fastest download speeds and reliability in Prescott. In Idaho, the company received multiple recognitions for download speed, responsiveness and reliability in Boise, Lewiston and McCall. Fastest upload speed recognitions were also earned by Sparklight in Ontario, Oregon-Idaho and Sandoval County, New Mexico.

Reliable speeds, gaming and video results broaden performance signals

Overall speed is one measure of internet performance, but Speedtest Intelligence® results also assess other aspects of the connectivity experience.

Sparklight earned 16 recognitions for Most Reliable Internet Speeds. The company also received recognition for Best Fixed Gaming Experience in North Dakota and Best Fixed Video Experience in the Albuquerque, New Mexico, area.

Taken together, the categories provide six distinct internet performance measures: download speed, upload speed, responsiveness, reliability in speed, gaming experience and video experience. This gives consumers information beyond a single speed measurement when comparing how fixed internet services perform across different types of everyday use.

Network investment expands capacity and Multi-Gig internet availability

The Ookla results come as Sparklight continues to strengthen and expand its fiber-rich network across the communities it serves.

Over the past three years, the company has invested nearly $1 billion across its 24-state footprint to increase network capacity, expand Multi-Gig internet availability and enhance reliability.

Sparklight also offers Mobile service to its internet customers, providing connectivity at home and on the go.

More information about Sparklight’s high-speed internet services is available at Sparklight.com.

* Based on Ookla® Speedtest Intelligence® data for Q1–Q2 2026. Ookla trademarks used under license and reprinted with permission.
** Based on analysis of Ookla® Speedtest Intelligence® data, 1H 2026, in Sparklight service footprint. All rights reserved.

About Sparklight
Sparklight is a leading broadband communications provider delivering exceptional service and enabling approximately 1 million residential and business customers across 24 states to thrive and stay connected to what matters most. Through Sparklight®, the brand our customers know and trust, we’re not just shaping the future of connectivity – we’re transforming it with a commitment to innovation, reliability and customer experience at our core.

Our robust infrastructure and cutting-edge technology don’t just keep our customers connected; they help drive progress in education, business and everyday life. We’re dedicated to bridging the digital divide, empowering our communities and fostering a more connected world. When our customers choose Sparklight, they are choosing a team that is always working for them — one that believes in the relentless pursuit of reliability, because being a trusted neighbor isn’t just what we do — it’s who we are.

CONTACT:
Trish Niemann
Vice President, Communications Strategy
trish.niemann@cableone.biz

FREQUENTLY ASKED QUESTIONS

Question: How did Sparklight perform in Ookla’s internet performance results during the first half of 2026?
Answer: Sparklight earned 86 Ookla recognitions across 14 states based on Speedtest Intelligence data for the first half of 2026. The largest categories were Fastest Download Speeds, with 33 recognitions, and Most Responsive Internet Speeds, with 27.

Question: What are Sparklight’s 86 Ookla recognitions for?
Answer: The recognitions span six internet performance categories: fastest download speeds, most responsive internet speeds, most reliable internet speeds, fastest upload speeds, best fixed gaming experience and best fixed video experience. The results are based on Speedtest Intelligence data from millions of consumer-initiated tests conducted between Jan. 1 and June 30, 2026.

Question: Which internet performance categories earned Sparklight the most recognition?
Answer: Fastest Download Speeds was Sparklight’s largest category with 33 recognitions. It was followed by Most Responsive Internet Speeds with 27 and Most Reliable Internet Speeds with 16. Together, those three categories accounted for 76 of the company’s 86 recognitions.

Question: Where did Sparklight receive Ookla internet performance recognitions?
Answer: The 86 recognitions span 14 states. The announcement identifies performance highlights in markets and areas across Arizona, Idaho, Illinois, Indiana, Kansas, Louisiana, Mississippi, Missouri, New Mexico, North Dakota, Oklahoma, Oregon, South Carolina and Texas.

Question: How do Sparklight’s internet speeds compare with 5G Home Internet?
Answer: Based on a custom analysis of Ookla® Speedtest Intelligence® data across Sparklight’s service footprint, Sparklight internet speeds were 50% faster than 5G Home Internet. Sparklight upload speeds were 73% faster than 5G Home Internet.

Question: Did Sparklight receive recognition for gaming and streaming performance?
Answer: Yes. Sparklight received Best Fixed Gaming Experience recognition in North Dakota and Best Fixed Video Experience recognition in the Albuquerque, New Mexico, area.

Question: Are the Sparklight Ookla results based on customer internet tests?
Answer: Yes. The recognitions are based on Speedtest Intelligence data drawn from millions of consumer-initiated tests conducted during the first half of 2026. The measurement period ran from Jan. 1 through June 30, 2026.

PUBLISHED RESEARCH & RESOURCES

• Sparklight high-speed internet services: https://www.sparklight.com/
• Sparklight Mobile: http://www.sparklight.com/mobile
• Ookla Speedtest Intelligence: https://www.ookla.com/resources/guides/speedtest-methodology

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9121d1db-572b-4d3a-a899-5d798099ac94

Company Reviews Significant Ophthalmology, Intellectual Property and Translational Development Milestones Achieved Over the Past Year

Palm Beach Gardens, FL, Sept. 11, 2026 (GLOBE NEWSWIRE) — Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company advancing topical metformin-based ophthalmic therapies for degenerative eye diseases, today issued the following letter to shareholders and interested investors reviewing the Company’s progress over the past year and outlining its priorities as it advances its ophthalmology platform.

Dear Fellow Shareholders and Interested Investors:

When we last wrote to shareholders in November 2025, we outlined a new strategic direction for Curative Biotechnology centered on advancing our metformin-based ophthalmology platform while establishing a more focused development strategy and capital structure.

Over the past year, we have made meaningful progress toward those objectives. We have expanded our intellectual property portfolio in both the United States and Canada, established an important translational research collaboration with the University of Pennsylvania’s School of Veterinary Medicine, advanced our human and veterinary development strategies, and completed a significant restructuring of our capital structure.

We believe these milestones have strengthened the scientific, intellectual property and translational foundation supporting our lead metformin-based topical ophthalmic program and positioned Curative for its next stage of development.

Expanding Our Global Intellectual Property Portfolio

During 2026, Curative achieved important intellectual property milestones for its metformin-based ophthalmology platform.

In January, the Company announced that the Canadian Intellectual Property Office had issued a Notice of Allowance for the patent application entitled “Druggable Target to Treat Retinal Degeneration.”

In July, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 17/642,610 covering methods directed to topical ophthalmic administration of metformin for retinal degeneration. The allowed claims include Age-Related Macular Degeneration (AMD), retinal pigment epithelium degeneration, and both Stargardt’s disease and Stargardt’s-like disease, utilizing pharmaceutical compositions formulated for topical ocular delivery as eye drops.

These allowances expand the global intellectual property portfolio supporting technology for which Curative is the exclusive worldwide licensee pursuant to a patent license agreement with the National Eye Institute (NEI), part of the National Institutes of Health (NIH).

Advancing Translational Ophthalmology Through PennVet

In May, Curative entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (PennVet) to support a study evaluating the Company’s metformin-based topical ophthalmic formulation in a canine model of retinal degeneration.

The study, led by Valérie L. Dufour, DVM, MSc, Assistant Professor of Translational Ophthalmology at PennVet, is designed to generate translational data supporting both the Company’s veterinary ophthalmology initiatives and its broader human ophthalmology development strategy.

The veterinary program provides Curative with an opportunity to evaluate its topical metformin platform in naturally occurring retinal disease while also pursuing potential veterinary development pathways. We believe the translational nature of this work may provide important insights applicable to the Company’s broader ophthalmology program.

Advancing the Human Clinical Development Pathway

Curative continues to advance its lead metformin-based topical ophthalmic formulation for intermediate and late-stage Age-Related Macular Degeneration.

The Company’s planned first-in-human clinical study will be conducted by the National Eye Institute under Curative’s Cooperative Research and Development Agreement (CRADA) with the NEI. The Company’s development strategy continues to benefit from the scientific foundation established through its relationship with the NEI and the underlying technology developed under the leadership of Dr. Kapil Bharti and his team.

Curative has commenced cGMP manufacturing of its metformin-based topical ophthalmic formulation to produce clinical supply for the Company’s planned first-in-human study. This represents an important step in advancing the program toward clinical evaluation.

Strengthening Our Capital Structure

In March 2026, Curative completed a 1-for-150 reverse stock split of its common stock, reducing approximately 1.02 billion outstanding common shares to approximately 6.8 million shares at the time of the transaction.

The restructuring was undertaken as part of the Company’s broader effort to establish a more appropriate capital structure, improve its positioning within the public markets and support access to a broader range of potential investors as the Company advances its development programs.

Management continues to evaluate opportunities to strengthen the Company’s capital position and engage with potential strategic and institutional investors whose interests align with Curative’s long-term development strategy.

Growing Awareness of Curative’s Drug-Repurposing Strategy

Curative’s metformin ophthalmology program was recently highlighted in a USA TODAY Contributor Content article examining the growing scientific interest in studying established medicines for new therapeutic applications.

The article discusses Curative’s development of a topical metformin eye-drop formulation for retinal disease, the Company’s relationship with the National Eye Institute, and the broader scientific rationale behind drug repurposing.

Read the USA TODAY article: “Why Old Drugs Keep Getting New Research Questions”

We believe growing awareness of Curative’s scientific strategy can help introduce the Company and its development programs to a broader audience of investors, researchers and potential strategic partners.

Looking Ahead

As we look toward the remainder of 2026 and beyond, our priorities are clear.

We intend to continue advancing the clinical and translational development of our metformin-based ophthalmology platform, strengthen the manufacturing and development infrastructure required to support our programs, expand our intellectual property position, and pursue the capital and strategic relationships necessary to move these programs forward.

Drug development requires patience, disciplined execution and access to capital. While challenges are inherent in building an emerging biotechnology company, we believe the progress achieved over the past year has materially strengthened Curative’s foundation.

Our objective remains unchanged: to translate promising science into meaningful therapeutic opportunities while building long-term value for our shareholders.

We appreciate the continued support and confidence of our shareholders as we work toward the next stage of Curative Biotechnology’s development.

Sincerely,
Paul Michaels
Executive Chairman
Curative Biotechnology, Inc.

Future Curative Biotechnology Press Releases and Updates

Interested shareholders and investors may request notification of future press releases and corporate updates by emailing ir@curativebiotech.com.

About Curative Biotechnology, Inc.

Curative Biotechnology, Inc. is a development-stage biomedical company focused on novel therapeutic approaches for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with an emphasis on rare disease indications. Curative currently maintains programs in degenerative eye disease, infectious disease, and neuro-oncology.

The Company’s primary focus is its metformin-based ophthalmology platform, supported by a worldwide exclusive license from the National Eye Institute (NEI), part of the National Institutes of Health (NIH), and a growing global intellectual property portfolio. Its lead therapeutic candidate is a metformin-based topical ophthalmic formulation being developed for the treatment of intermediate- and late-stage Age-Related Macular Degeneration (AMD). Through strategic manufacturing, translational research, and intellectual property initiatives, the Company is also advancing complementary veterinary ophthalmology programs as part of its broader development strategy.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements regarding intellectual property protection, clinical and translational development activities, manufacturing and development activities, regulatory pathways, capital requirements, strategic relationships, potential financing, and the potential therapeutic applications of the Company’s metformin-based ophthalmology platform. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include uncertainties relating to intellectual property protection, regulatory approvals, clinical development outcomes, manufacturing, reliance on third-party collaborators, availability of capital, market acceptance, and the Company’s ability to execute its business strategy. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Contact
Paul Michaels
Executive Chairman
Direct: 917-492-8855
Investor Relations
Curative Biotechnology, Inc. (CUBT)
ir@curativebiotech.com

SHENZHEN, China, Sept. 11, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced that it has partnered with Bank of Hangzhou Co., Ltd. (“Bank of Hangzhou”) to enhance the underlying messaging infrastructure of the bank’s mobile banking systems. Aurora Mobile’s intelligent push notification solution, JPush, has officially been integrated into Bank of Hangzhou’s mobile banking app. The collaboration is designed to support more reliable, timely, and secure message delivery for mobile banking users.

Overcoming System-Level Background Restrictions to Support Millisecond-Level Delivery of Transaction Notifications

As mobile banking services become increasingly sophisticated, push notifications have become a critical underlying capability.

Mobile banking apps have evolved beyond simple account inquiry tools to cover wealth management, lending and full-lifecycle customer engagement. Notifications related to account transactions, large-value transfers and risk confirmations require highly timely delivery.

Mobile operating systems’ background management mechanisms may affect notification delivery. When users switch an app to the background or leave it idle for an extended period, power-saving mechanisms may clear or put the app to sleep, causing transaction notifications sent by the bank’s backend to be blocked or delayed. This can affect the user experience and raise concerns about fund security.

By integrating JPush, Bank of Hangzhou has strengthened its underlying messaging capabilities. JPush supports Android, iOS, HarmonyOS, QuickApp and Web, and integrates Aurora Mobile’s own push channels, FCM, APNs, and system-level push channels from major device manufacturers, including Huawei, Xiaomi, OPPO, vivo, Meizu, ASUS and others.

Through standardized APIs, mobile apps can connect to mainstream system-level push channels. Even when a mobile banking app is offline or in the background and subject to system sleep, high-priority financial notifications can still reach users in a timely and reliable manner through native operating system notifications.

Protecting Sensitive Data Through a Secure and Compliant Architecture

The financial industry has strict compliance requirements for the adoption of third-party technology components. Data privacy and information security are non-negotiable.

Aurora Mobile and Bank of Hangzhou have placed security and compliance at the forefront of the design and operation of the entire business process. The Company’s system architecture strictly follows the principle of collecting only the data necessary for the service, while supporting strong encryption throughout the transmission process.

In practice, JPush is strictly limited to serving as a “messaging channel.” It is responsible only for rapidly delivering encrypted instructions and does not parse or access any sensitive banking data contained within them.

This dual layer of physical and logical isolation is aligned with the stringent audit requirements of regulatory authorities regarding data privacy and cybersecurity in financial institutions.

Abstracting Underlying Differences to Free Up IT Resources

In addition to strengthening its messaging capabilities, JPush also helps reduce the operational and maintenance burden on the bank’s technology team.

With numerous mobile device brands in China, push interfaces, platform rules and compliance requirements across manufacturers are frequently changing. Having bank developers connect to and maintain these underlying channels individually would require considerable IT resources.

Through a unified SDK, Aurora Mobile takes on the adaptation and ongoing maintenance of multiple terminals and operating systems.

This allows Bank of Hangzhou’s engineers to move away from cumbersome underlying integrations and devote more of their development resources and attention to core financial product development and the optimization of online business logic.

Bank of Hangzhou’s adoption of JPush represents a practical enhancement of its underlying mobile messaging capabilities, helping ensure that information is delivered reliably, quickly and securely.

About Aurora Mobile Limited

Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit https://ir.aurora-mobile.com/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

Christensen Advisory
Ms. Xiaoyan Su
E-mail: Xiaoyan.Su@christensencomms.com

U.S.-based digital infrastructure company that develops and operates power-intensive bitcoin mining and computing facilities across Oklahoma, Arkansas and Ohio

Irvine & Los Angeles, CA, Sept. 11, 2026 (GLOBE NEWSWIRE) — Aperture AC (NASDAQ: APUR), a special purpose acquisition company (“Aperture”), and Atlantic HPC Group Inc. (“Atlantic”), a U.S.-based digital infrastructure company that develops and operates power-intensive bitcoin mining and computing facilities across Oklahoma, Arkansas and Ohio, today announced the signing of a definitive business combination agreement (the “Business Combination Agreement”) for a business combination (the “Proposed Business Combination”) that is expected to result in the combined company becoming a publicly listed company. Upon closing of the transaction, subject to approval by Aperture’s shareholders and Atlantic’s stockholders and other customary closing conditions, the combined company intends to be traded on Nasdaq under the ticker symbol “AHPC” and Aperture is expected to be renamed Atlantic HPC Corp., or such other name as Atlantic will determine. The transaction is expected to close in the first quarter of 2027, subject to applicable exchange, regulatory and shareholder approvals and the satisfaction of other closing conditions. Concurrently with the issuance of this press release, Aperture has filed an investor presentation outlining Atlantic’s business and the Proposed Business Combination, including the following investment highlights:

●             Large and Growing Addressable Market: AI Growth is Driving Power Demand & Infrastructure Spend

o                      According to McKinsey & Company (April 2025), global data center capacity demand for AI workloads is projected to reach 156 gigawatts by 2030, a 3.5x increase over 2025 levels, requiring an estimated $5.2 trillion of capital expenditures¹
o                      This growth is expected to be driven by strong demand for AI compute globally

●             Growth Constrained Grid Provides Opportunity

o                      Data center power grid interconnection lead times now average three to seven years in the U.S. with the interconnection queue currently 1.5x total U.S. installed capacity^{2 3}
o                      Atlantic’s existing utility relationships, in-place power infrastructure and operating sites are expected to support faster time to market for new data center development

●             Sizeable Development Platform

o                      Total development pipeline of 121 MW across 6 sites

¹      https://www.mckinsey.com/industries/technology-media-andtelecommunications/%20our-insights/the-cost-of-compute-a-7-trillion-dollar-race-to-scale-data-centers 
²      Benjamin Jordan, Senior Director of Integrated Planning, CPS Energy, PowerGen International 2026, San Antonio, TX
³      https://emp.lbl.gov/sites/default/files/2026-06/Queued%20Up%202026%20Edition.pdf

o                      98 MW of utility-approved power capacity, of which 51 MW is currently in operation⁴ serving bitcoin mining⁵ and 47 MW is under development⁶
o                      An additional 23 MW is held for future development⁷
o                      Facilities located in Oklahoma, Arkansas and Ohio

●             Strong Revenue, EBITDA and Mining Metrics in FY2026A⁸

o                      FY2026A revenue of $28.6 million
o                      FY2026A EBITDA of $4.4 million
o                      1.9 EH/s hash rate
o                      303 bitcoin mined in FY2026A

●             Anticipated Capital and Resource Efficient Leasing Strategy

o                      Atlantic intends to provide a powered shell developed to a design standard that Atlantic believes will be generally consistent with Tier III concurrent-maintainability principles
o                      Under the anticipated leasing structure, the tenant would provide all cooling, rack buildout, IT equipment, including GPUs, servers, storage, and networking and all other equipment and connections necessary to operate the tenant’s workloads at the premises
o                      Base rent is expected to be paid on contracted power capacity and electricity is expected to be billed to the tenant based on usage on a pass-through basis

●             Positioned to Expand into the Growing AI / HPC Infrastructure Sector

o                      High-performance computing sector experiencing rapid growth and attracting significant investor capital
o                      Active and well-defined public comparable group of bitcoin mining companies that have diversified or intend to diversify their operations into AI compute

Atlantic seeks to support growing demand for computation by developing efficient high-performance computing infrastructure.

⁴      Sites in operation are those where construction is complete and the facility is commissioned, energized, and capable of serving customer or company compute loads
⁵      9 MW of utility-approved capacity allocated to bitcoin mining at Alledonia, OH is currently offline while mining hardware is upgraded
⁶      Sites under development are those where Atlantic has secured both the land (owned, or under a definitive lease or purchase agreement) and power (an executed power supply or interconnection agreement for a specified capacity), but where construction has not commenced
⁷      Sites held for future development are those where Atlantic holds an executed land instrument or a written utility capacity allocation, but not yet both land and power under executed definitive agreements. Targeted MW is a management estimate supported by written analysis and is not included in totals of executed capacity
⁸      Atlantic fiscal year ended 6/30/2026, FY 2026A is actual but unaudited.

“We’re excited to partner with the Aperture team which brings substantial expertise across capital markets, energy and data-center infrastructure,” said Atlantic CFO Benson Liu. Mr. Liu continued, “we believe being a public company will support our ability to scale rapidly through increased financial flexibility and bolster our credibility as a long-term partner to our customers.”

“We are excited to reach this important milestone with Atlantic. We believe that Atlantic is an exceptional company with which to complete a business combination,” said Aperture Chief Executive Officer Calvin Kung. Mr. Kung continued, “the company has established an operating digital infrastructure platform through its bitcoin mining operations and is developing infrastructure to serve multiple key end markets including the attractive and high-growth high-performance computing sector. Atlantic’s existing operational facilities as well as its development pipeline, including the Ohio AI Campus, provide a strong platform that we believe can scale rapidly. We believe a public listing will provide Atlantic with enhanced visibility, commercial opportunities and financial flexibility to execute its business plan and achieve its next leg of growth and scale. We look forward to working with Atlantic’s management team to consummate the Proposed Business Combination.”

Transaction Overview

Pursuant to the Business Combination Agreement, Aperture will acquire Atlantic for a pre-money equity value of $150 million, payable in shares of Aperture, with each share valued at $10.00. The Proposed Business Combination will be structured as a merger, whereby a newly formed wholly owned subsidiary of Aperture will merge with and into Atlantic, with Atlantic surviving the merger and becoming a wholly owned subsidiary of Aperture. In consideration for the merger, Aperture will issue 15,000,000 shares of Class A common stock to the current stockholders of Atlantic. The Atlantic stockholders as of immediately prior to the closing will also receive the contingent right to receive up to 6,000,000 additional shares of Aperture Class A common stock (such shares, the “Earnout Shares”), subject to the achievement of the following milestones:

1.             Operational milestone: 3,000,000 Earnout Shares will be issued upon the execution of a binding, arm’s-length lease for the Phase I capacity (5 megawatt) of the Company’s data center, with a tenant that is not an affiliate of Atlantic and whose obligations are not funded or guaranteed by Atlantic or its stockholders, and an initial non-cancelable term of at least seven (7) years 
2.             Share price milestones: 1,500,000 Earnout Shares will be issued if the volume-weighted average price of the combined company’s common stock over any three consecutive calendar months equals or exceeds $12.50 per share, and an additional 1,500,000 Earnout Shares will be issued if such volume-weighted average price over any three consecutive calendar months equals or exceeds $15.00 per share 

Atlantic stockholders are expected to roll 100% of their equity into the combined company. The transaction is expected to provide up to $102 million in gross proceeds from cash held in the Aperture trust account, assuming no redemptions by Aperture’s public shareholders and before accounting for expected transaction expenses. Prior to the closing of the Proposed Business Combination, Aperture shall de-register from the Register of Companies of the Cayman Islands and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation.

The boards of directors of Atlantic and Aperture have unanimously approved the transaction. The transaction is expected to close in the first quarter of 2027, subject to applicable exchange, regulatory and shareholder approval and satisfaction of other closing conditions.

Additional information regarding the Proposed Business Combination, including a copy of the business combination agreement and other relevant materials, will be provided by Aperture on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”).

Advisors

Hunter Taubman Fischer & Li LLC is acting as legal advisor to Atlantic. Ellenoff Grossman & Schole LLP is acting as legal advisor to Aperture.

About Atlantic HPC Group Inc.

Founded in 2024 and headquartered in Irvine, CA, Atlantic is a U.S.-based digital infrastructure company that develops and operates power-intensive bitcoin mining and computing facilities across Oklahoma, Arkansas, and Ohio. Atlantic is currently primarily engaged in cryptocurrency mining operations, including self-mining and cryptocurrency mining colocation services, and substantially all of Atlantic’s revenue to date has been generated from bitcoin mining. Building on its expertise in power procurement and high-performance operations, Atlantic is expanding into AI infrastructure through its Ohio AI Campus, for which utility-approved power capacity has been contracted, subject to the approved usage terms of the applicable utility agreements and additional infrastructure upgrades required prior to full commercial operation. For more information, visit https://ahpc.com/.

About Aperture AC

Aperture AC (NASDAQ: APUR) is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses with a focus on identifying and acquiring companies in the digital asset industry. For additional information, please visit https://apertureac.com/.

Additional Information and Where to Find It

This press release is provided for information purposes only and contains information with respect to a Proposed Business Combination among Atlantic, Aperture and AP Ocean Merger Sub, Inc., a wholly-owned subsidiary of Aperture, in connection with the transactions contemplated in the business combination agreement. In connection with the Proposed Business Combination, Aperture intends to file with the SEC a registration statement on Form S-4, which will include a definitive proxy statement to be mailed to Aperture shareholders and a prospectus for the registration of Aperture securities in connection with the Proposed Business Combination (as amended from time to time, the “Registration Statement”). A full description of the terms of the Proposed Business Combination will be provided in the Registration Statement. Aperture urges investors, shareholders and other interested persons to read, when available, the Registration Statement as well as other documents filed with the SEC because these documents will contain important information about Aperture, Atlantic and the Proposed Business Combination. If and when the Registration Statement is declared effective by the SEC, the definitive proxy statement/prospectus and other relevant documents will be mailed to shareholders of Aperture as of a record date to be established for voting on the Proposed Business Combination. Aperture will also file other documents regarding the Proposed Business Combination with the SEC. This Press Release does not contain all of the information that should be considered concerning the Proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Proposed Business Combination. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, SHAREHOLDERS OF APERTURE AND OTHER INTERESTED PARTIES ARE URGED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT/PROSPECTUS, AND AMENDMENTS THERETO, AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH APERTURE’S SOLICITATION OF PROXIES FOR THE EXTRAORDINARY GENERAL MEETING OF ITS SHAREHOLDERS TO BE HELD TO APPROVE THE PROPOSED BUSINESS COMBINATION AND OTHER MATTERS AS DESCRIBED IN THE PROXY STATEMENT/PROSPECTUS BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT APERTURE AND ATLANTIC AND THE PROPOSED BUSINESS COMBINATION.

Shareholders and other interested persons will also be able to obtain a copy of the Registration Statement, without charge, by directing a request to: Aperture AC, 835 Wilshire Blvd. 5th Floor, Los Angeles, CA 90017. The proxy statement/prospectus, once available, can also be obtained, without charge, at the SEC’s website (www.sec.gov). The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTIONS OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS REPORT. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

No Offer or Solicitation

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any vote, consent or approval in any jurisdiction in respect of the Proposed Business Combination, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This press release does not constitute either advice or a recommendation regarding any securities. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Participants in the Solicitation

Aperture and Atlantic and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the Proposed Business Combination described herein under the rules of the SEC. Information about the directors and executive officers of Aperture and a description of their interests in Aperture and the Proposed Business Combination are, or will be, contained in Aperture’s filings with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Aperture’s shareholders in connection with the Proposed Business Combination will be set forth in the proxy statement/prospectus for the Proposed Business Combination, when available. Additional information regarding the interests of participants in the solicitation of proxies in connection with the Proposed Business Combination will be included in the proxy statement/prospectus that Aperture intends to file with the SEC. Once available, you may obtain free copies of these documents as described above.

Forward-Looking Statements

The disclosure herein includes certain statements that are not historical facts but are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, (1) statements regarding estimates and forecasts of other financial, performance and operational metrics and projections of market opportunity; (2) references with respect to the anticipated benefits of the Proposed Business Combination and the projected future financial performance of Atlantic following the Proposed Business Combination; (3) changes in the market for Atlantic’s services and technology, expansion plans and opportunities; (4) Atlantic’s unit economics; (5) the sources and uses of cash in connection with the Proposed Business Combination; (6) the anticipated capitalization and enterprise value of the combined company following the consummation of the Proposed Business Combination; (7) the projected technological developments of Atlantic; (8) current and future potential commercial and customer relationships; (9) the ability to operate efficiently at scale; (10) anticipated investments in capital resources and research and development, and the effect of these investments; (11) the amount of redemption requests made by Aperture’s public shareholders; (12) the ability of the combined company to issue equity or equity-linked securities in the future; (13) the failure to achieve necessary closing requirements; (14) the inability to obtain or maintain the listing of the combined company’s common stock on a national securities exchange following the Proposed Business Combination, including but not limited to redemptions exceeding anticipated levels or the failure to meet the exchange’s initial listing standards in connection with the consummation of the Proposed Business Combination; (15) the development, construction and commercialization of the Ohio AI Campus and Atlantic’s planned transition from Bitcoin mining to AI/HPC infrastructure services; (16) the ability to convert existing letters of intent into definitive customer agreements on acceptable terms; (17) the ability to obtain required utility approvals, interconnection agreements and infrastructure upgrades necessary for Atlantic’s development projects; (18) expectations related to the terms and timing of the Proposed Business Combination; (19) volatility in the price of Bitcoin, changes in network difficulty and the effect of halving events; (20) Atlantic’s dependence on a single mining pool operator for substantially all of its revenue; (21) Atlantic’s fixed-delivery hashrate purchase and sale arrangements and the related derivative liability, including the consequences of non-delivery; and (22) the reallocation of existing digital asset mining capacity to AI/HPC use and the resulting effect on mining revenue.

These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Aperture’s and Atlantic’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Aperture and Atlantic. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to: the risk that the transactions contemplated by the Business Combination Agreement, including the domestication and the merger (the “Transactions”), may not be completed in a timely manner or at all, which may adversely affect the price of Aperture’s securities; the risk that the Transactions may not be completed by Aperture’s business combination deadline; the failure by the parties to the Business Combination Agreement to satisfy the conditions to the consummation of the Transactions, including the approval of Aperture’s shareholders; failure to realize the anticipated benefits of the Transactions; the level of redemptions of Aperture’s public shareholders which may reduce the public float of, reduce the liquidity of the trading market of, and/or maintain the quotation, listing, or trading of the Aperture common stock; the failure of Aperture to obtain or maintain the listing of its securities on any national securities exchange on which Aperture common stock will be listed after the closing of the Proposed Business Combination (the “Closing”); costs related to the Transactions and as a result of becoming a public company; changes in business, market, financial, political and regulatory conditions; Atlantic has historically derived substantially all of its revenue to date from bitcoin mining operations and remains heavily dependent on bitcoin mining for the foreseeable future; volatility in the price of bitcoin and increases in network difficulty may adversely affect Atlantic’s mining revenue and profitability; Atlantic’s dependence on a single mining pool operator for substantially all of its mining revenue, and the ability of the pool operator to adjust fee rates; Atlantic’s AI/HPC infrastructure business has not generated material revenue to date, and there can be no assurance that Atlantic will successfully execute its planned transition from bitcoin mining to AI/HPC infrastructure services or that it will secure definitive customer agreements for such services; the development of the Ohio AI Campus is in its early stages, with additional utility approvals, interconnection agreements and infrastructure upgrades required before full commercial operation, the timing and outcome of which are uncertain; Atlantic has a limited operating history and a small workforce, which may limit its ability to execute its growth strategy and respond to operational demands; Atlantic’s fixed-delivery hashrate purchase and sale arrangements and the related derivative liability, including the consequences of non-delivery of bitcoin under such arrangements; concentration of Atlantic’s equipment supply chain among a limited number of suppliers; Atlantic holds all mined digital assets in self-custody without a third-party custodian, and does not currently maintain insurance covering loss or theft of digital assets; Atlantic’s facilities are located in a limited number of states, and any adverse regulatory, environmental or utility-related development affecting those jurisdictions could disproportionately affect Atlantic’s operations; the reallocation of existing digital asset mining capacity at the Ohio site to AI/HPC use and the resulting effect on mining revenue; and those risk factors discussed in the Registration Statement and the other documents that Aperture has filed, or will file, with the SEC relating to the Proposed Business Combination. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. The risks and uncertainties above are not exhaustive, and there may be additional risks that neither Aperture nor Atlantic presently know or that Aperture and Atlantic currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aperture’s and Atlantic’s expectations, plans or forecasts of future events and views as of the date of this press release. Aperture and Atlantic anticipate that subsequent events and developments will cause Aperture’s and Atlantic’s assessments to change. However, while Aperture and Atlantic may elect to update these forward-looking statements at some point in the future, Aperture and Atlantic specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Aperture’s and Atlantic’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts
Aperture AC
835 Wilshire Blvd., 5th Floor
Los Angeles, CA 90017
Attn: Calvin Kung, CEO
(424) 253-0908

Atlantic Investor Contact:
For media inquiries: pr@ahpc.com 
For investor inquiries: ir@ahpc.com